EOAR SEMINAR, AUGUST 2022
The Human Pluripotent Stem Cell Registry (hPSCreg): Ethical framework for hPSC cell line research in Europe
Dr Nancy Mah, Prof Andreas Kurtz, Dr Antonie Fuhr, Dr Sabine Müller (Fraunhofer Institute for Biomedical Engineering)
The human embryonic stem cell registry was initiated in 2007 with funding from the European Commission (EC) in response to an emerging technology, namely human embryonic stem cells, in order to help manage ethical and scientific uncertainties. A main focus of the initiative was to build public trust in oversight of this technology, and in the EU funding policy. Following the discovery of human induced pluripotent stem cells and their rapid uptake by the research community, the Registry was renamed the human pluripotent stem cell registry (hPSCreg) in the second EC funding period. A third funding period (Horizon 2020) funding ensured the continued operation of hPSCreg, during which the Registry continued to track the use of human pluripotent stem cells and expanded the knowledgebase to include a database of clinical studies that involved the use of hPSC-derived cell therapy products. Today, hPSCreg continues to be supported by another round of EC funding (Horizon Europe). While the original aim for funding hPSCreg persists, the scientific community realizes the additional need to promote reproducibility of research. In this webinar, we describe the ethical motivation behind the Registry's beginnings and its continued international development.
When: Monday, 29th August 2022, 3:30-4:30 PM (ACST)
Where: Online. Please RSVP to firstname.lastname@example.org